Thymagen (Thymogen) is a synthetic dipeptide bioregulator composed of glutamic acid and tryptophan (Glu–Trp; EW). The compound has been investigated in experimental systems modeling thymus-associated immune differentiation and intracellular signal-transduction processes. Early work described isolation from thymic tissue sources, while contemporary material is produced by controlled synthetic methods for laboratory research.

Within peer-reviewed literature, Thymagen has been evaluated as a modulator of intracellular second-messenger pools, particularly cyclic nucleotide systems, and as a research tool for examining maturation and functional regulation of lymphoid cell populations in thymus and spleen models. These investigations focus on biochemical signaling efficiency, intracellular messenger turnover, and downstream transcriptional or cytokine-associated pathways.

Thymic peptide bioregulators are frequently studied to better understand immune-cell development. In this context, Thymagen has been used experimentally to explore relationships between altered intracellular signaling environments and changes in lymphocyte differentiation markers, effector-cell functional properties, and immune signaling coordination.

Amino Acid Sequence: Glu-Trp (EW)
Molecular Formula: C16H19N3O5
Molecular Weight: 333.34 g/mol
PubChem CID: 100094
CAS Number: 38101-59-6
Synonyms: Oglufanide, Thymogen

Source: PubChem

As a low–molecular weight dipeptide, Thymagen provides a simplified structural platform for studying peptide–enzyme and peptide–receptor interactions relevant to thymus-derived regulatory signaling. Laboratory handling emphasizes maintenance of peptide integrity and compatibility with chromatographic and spectrometric analytical workflows.

Thymagen is utilized in research environments as a biochemical probe for immune-associated signaling and differentiation studies. Common experimental applications described in the literature include:

• Second-messenger signaling studies: evaluation of cyclic nucleotide pools, phosphodiesterase activity, and downstream kinase signaling in lymphoid cells.
• Immune differentiation models: examination of T-lymphocyte precursor maturation and phenotypic transitions in thymus and spleen systems.
• Cytokine and interferon pathway assays: measurement of interferon-associated signaling outputs and transcriptional markers.
• Host-response challenge models: controlled animal experiments assessing immune signaling allocation during defined microbial exposure paradigms.
• Tissue stress-response systems: exploratory use in isolated tissue preparations to study biochemical responses under controlled stress conditions.

Endpoints in these studies are biochemical, cellular, or molecular in nature and are consistent with research-only investigation frameworks.

Cyclic nucleotides function as intracellular second messengers that relay signals from membrane-associated receptors to downstream effector systems. In immune-cell contexts, cyclic AMP and cyclic GMP integrate signaling inputs that influence transcriptional activity, activation thresholds, and differentiation trajectories.

Experimental reports describe Thymagen-associated modulation of cyclic nucleotide catabolism, resulting in elevated intracellular nucleotide pools under controlled conditions. Increased availability of these messengers can amplify downstream signaling cascades and alter gene-expression programs relevant to immune-cell maturation.

Source: PubChem

In thymus and spleen tissue models, shifts in cyclic GMP signaling have been correlated with progression of T-lymphocyte precursors toward immunocompetent phenotypes. Additional work has associated Thymagen exposure with interferon-related signaling activity, positioning the peptide as a tool for studying innate immune coordination mechanisms.

Preclinical investigations have evaluated Thymagen in lymphoid tissue systems, controlled microbial challenge models, metabolic-disease-associated immune dysfunction paradigms, and isolated tissue stress experiments. These studies emphasize immune differentiation markers, cytokine-associated signaling profiles, and biochemical stress-response parameters rather than organism-level outcomes.

Rodent studies examining radiation exposure and chemically induced tumor models have explored relationships between thymic peptide signaling and immune surveillance metrics. Mechanistic interpretation in these reports centers on modulation of innate immune signaling and immune-cell functional allocation under experimental conditions.

Collectively, the preclinical literature positions Thymagen as a research reagent for studying immune-system signaling efficiency, differentiation control, and coordination of innate and adaptive immune responses in model systems.

Thymagen is supplied as a synthetic dipeptide for laboratory research. Common analytical characterization methods include:

• HPLC: assessment of chromatographic purity.
• Mass spectrometry: confirmation of molecular mass.
• Documentation: lot-specific analytical summaries where applicable.

The above literature was researched, edited, and organized by Dr. E. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology. Authorship attribution identifies the individual responsible for compiling and presenting the referenced scientific material in a research-focused format.

Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of genome peptide regulation” (Karger AG, 2005). Vladimir Khavinson introduced scientific specialty “Gerontology and Geriatrics” in the Russian Federation on the governmental level. Academic Council headed by V. Khavinson has oversighted over 200 Ph.D. and Doctorate theses from many different countries.

Prof. Vladimir Khavinson is being referenced as one of the leading scientists involved in the research and development of Thymagen. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.

1. S. V. Demidov, A. N. Kostromin, V. V. Kuĭbeda, I. V. Chernaia, and M. I. Borovok, “[Effect of thymagen, thymalin and vilosen on the cAMP and cGMP levels and phosphodiesterase activity in spleen lymphocytes during sensitization and anaphylactic shock],” Ukr. Biokhimicheskii Zhurnal 1978, vol. 63, no. 4, pp. 104–106, Aug. 1991.
2. A. L. Kozhemiakin, V. G. Morozov, and V. K. Khavinson, “[Participation of the cyclase system in the molecular mechanisms of differentiation control of immunocompetent cells],” Biokhimiia Mosc. Russ., vol. 49, no. 4, pp. 658–666, Apr. 1984.
3. D. S. Silin, O. V. Lyubomska, F. I. Ershov, V. M. Frolov, and G. A. Kutsyna, “Synthetic and natural immunomodulators acting as interferon inducers,” Curr. Pharm. Des., vol. 15, no. 11, pp. 1238–1247, 2009, doi: 10.2174/138161209787846847.
4. N. D. Iushchuk, G. I. Tseneva, T. V. Alenushkina, and L. B. Kuliashova, “[The efficacy of using thymogen in an experimental infection caused by Yersinia enterocolitica],” Zh. Mikrobiol. Epidemiol. Immunobiol., no. 3, pp. 106–108, Jun. 1995.
5. E. A. Zhuk and V. A. Galenok, “[Thymogen in the treatment of type-1 diabetes mellitus],” Ter. Arkh., vol. 68, no. 10, pp. 12–14, 1996.
6. O. K. Khmel’nitskiĭ, G. M. Iakovlev, V. L. Belianin, V. K. Khavinson, V. G. Morozov, and V. I. Deĭgin, “[The effect of a synthetic thymus peptide (thymogen) on the immune system in candidiasis under immunodepression],” Arkh. Patol., vol. 52, no. 1, pp. 20–25, 1990.
7. V. S. Smirnov, S. V. Petlenko, and S. S. El’tsin, “[Application thymogen for preoperative preparation of elderly patients with tumor processes in abdominal cavity],” Adv. Gerontol. Uspekhi Gerontol., vol. 24, no. 2, pp. 278–284, 2011.
8. K. M. Reznikov, O. V. Vinokurova, V. V. Alabovskiĭ, and A. A. Vinokurov, “[The anti-arrhythmia properties of thymogen],” Eksp. Klin. Farmakol., vol. 57, no. 6, pp. 31–33, Dec. 1994.
9. O. V. Filippova, K. M. Reznikov, V. V. Alabovskił, V. V. Khamburov, and A. A. Vinokurov, “[The effect of thymogen on the heart in ischemia and reperfusion],” Eksp. Klin. Farmakol., vol. 60, no. 3, pp. 27–29, Jun. 1997.
10. V. N. Anisimov, G. I. Miretskiĭ, V. G. Morozov, I. A. Pavel’eva, and V. K. Khavinson, “[The effect of the synthetic immunomodulator thymogen on radiation-induced carcinogenesis in rats],” Vopr. Onkol., vol. 38, no. 4, pp. 451–458, 1992.
11. V. G. Bespalov, D. N. Troian, A. S. Petrov, V. G. Morozov, and V. K. Khavinson, “[Inhibiting effect of thymogen on the development of tumors of the esophagus and forestomach induced by N-nitrososarcosine ethyl ester in rats],” Eksp. Onkol., vol. 11, no. 4, pp. 23–26, 1989.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.